Literature DB >> 221544

Human intestinal lipoproteins. Studies in chyluric subjects.

P H Green, R M Glickman, C D Saudek, C B Blum, A R Tall.   

Abstract

To explore the role of the human intestine as a source of apolipoproteins, we have studied intestinal lipoproteins and apoprotein secretion in two subjects with chyluria (mesenteric lymphatic-urinary fistulae). After oral corn oil, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II) output in urine increased in parallel to urinary triglyceride. One subject, on two occasions, after 40 g of corn oil, excreted 8.4 and 8.6 g of triglyceride together with 196 and 199 mg apoA-I and on one occasion, 56 mg apoA-II. The other subject, after 40 g corn oil, excreted 0.3 g triglyceride and 17.5 mg apoA-I, and, after 100 g of corn oil, excreted 44.8 mg apoA-I and 5.8 mg apoA-II. 14.5+/-2.1% of apoA-I and 17.7+/-4.3% of apoA-II in chylous urine was in the d < 1.006 fraction (chylomicrons and very low density lipoprotein). Calculations based on the amount of apoA-I and apoA-II excreted on triglyceride-rich lipoproteins revealed that for these lipid loads, intestinal secretion could account for 50 and 33% of the calculated daily synthetic rate of apoA-I and apoA-II, respectively. Similarly, subject 2 excreted 48-70% and 14% of the calculated daily synthetic rate of apoA-I and apoA-II, respectively. Chylous urine contained chylomicrons, very low density lipoproteins and high density lipoproteins, all of which contained apoA-I. Chylomicrons and very low density lipoproteins contained a previously unreported human apoprotein of 46,000 mol wt. We have called this apoprotein apoA-IV because of the similarity of its molecular weight and amino acid composition to rat apoA-IV. In sodium dodecyl sulfate gels, chylomicron apoproteins consisted of apoB 3.4+/-0.7%, apoA-IV 10.0+/-3.3%, apoE 4.4+/-0.3%, apoA-I 15.0+/-1.8%, and apoC and apoA-II 43.3+/-11.3%. Very low density lipoprotein contained more apoB and apoA-IV and less apoC than chylomicrons. Ouchterlony immunodiffusion of chylomicron apoproteins revealed the presence of apoC-I, apoC-II, and apoC-III. In contrast, plasma chylomicrons isolated during a nonchyluric phase revealed a markedly altered chylomicron apoprotein pattern when compared with urinary chylomicrons. The major apoproteins in plasma chylomicrons were apoB, apoE, and the C peptides: no apoA-I or apoA-IV were present in sodium dodecyl sulfate gels indicating that major changes in chylomicron apoproteins occur during chylomicron metabolism. When incubated in vitro with plasma, urinary chylomicrons lost apoA-I and apoA-IV and gained apoE and apoC. Loss of apoA-I and apoA-IV was dependent upon the concentration of high density lipoproteins in the incubation mixture. These studies demonstrate that the human intestine secretes significant amounts of apoA-I and apoA-II during lipid absorption. Subsequent transfer of apoproteins from triglyceride-rich lipoproteins to other plasma lipoproteins may represent a mechanism whereby the intestine contributes to plasma apoprotein levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221544      PMCID: PMC372110          DOI: 10.1172/JCI109444

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  On the reesterification of fatty acids during absorption of fat: studies in patients with chyluria.

Authors:  M L PETERSON
Journal:  Gastroenterology       Date:  1963-06       Impact factor: 22.682

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  The absorption of fats, studied in a patient with chyluria. I. Clinical investigation.

Authors:  R BLOMSTRAND; N A THORN; E H AHRENS
Journal:  Am J Med       Date:  1958-06       Impact factor: 4.965

4.  Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction.

Authors:  K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1978-09-10       Impact factor: 5.157

5.  Isolation and characterization of an apoprotein from the d less than 1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein.

Authors:  K H Weisgraber; T P Bersot; R W Mahley
Journal:  Biochem Biophys Res Commun       Date:  1978-11-14       Impact factor: 3.575

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  Rat intestine secretes discoid high density lipoprotein.

Authors:  P H Green; A R Tall; R M Glickman
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I.

Authors:  J Shepherd; C J Packard; J R Patsch; A M Gotto; O D Taunton
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

9.  Isolation and characterization of two threonine-poor apolipoproteins of human plasma high density lipoproteins.

Authors:  V G Shore; B Shore; S B Lewis
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

10.  Apoprotein A-I synthesis in normal intestinal mucosa and in Tangier disease.

Authors:  R M Glickman; P H Green; R S Lees; A Tall
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

View more
  37 in total

1.  Intestinal electric stimulation decreases fat absorption in rats: therapeutic potential for obesity.

Authors:  Ying Sun; Jiande Chen
Journal:  Obes Res       Date:  2004-08

2.  Immunogenetic polymorphism of lipoproteins in swine: genetic, immunological and physiochemical characterization of the two allotypes Lpr1 and Lpr2.

Authors:  J Rapacz; J Hasler-Rapacz; W H Kuo
Journal:  Genetics       Date:  1986-08       Impact factor: 4.562

3.  Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4).

Authors:  S K Karathanasis; P Oettgen; I A Haddad; S E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

4.  Selective evaluation of high density lipoprotein from mouse small intestine by an in situ perfusion technique.

Authors:  Satoshi Yamaguchi; Bo Zhang; Takeshi Tomonaga; Utako Seino; Akiko Kanagawa; Masaru Segawa; Hironori Nagasaka; Akira Suzuki; Takashi Miida; Sohsuke Yamada; Yasuyuki Sasaguri; Takefumi Doi; Keijiro Saku; Mitsuyo Okazaki; Yoshihiro Tochino; Ken-Ichi Hirano
Journal:  J Lipid Res       Date:  2014-02-25       Impact factor: 5.922

5.  Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.

Authors:  S Naganawa; H N Ginsberg; R M Glickman; G S Ginsburg
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

6.  Genetic studies of human apolipoproteins. I. Polymorphism of apolipoprotein A-IV.

Authors:  M I Kamboh; R E Ferrell
Journal:  Am J Hum Genet       Date:  1987-08       Impact factor: 11.025

Review 7.  High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11       Impact factor: 8.311

8.  Radioimmunoassay studies of human apolipoprotein E.

Authors:  C B Blum; L Aron; R Sciacca
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

9.  Apolipoprotein A-IV polymorphism in man.

Authors:  H J Menzel; P M Kövary; G Assmann
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

10.  Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.